In addition to a general section, the 2019 Drug Report offers analyses on antibiotics and clinically relevant drug combinations. With its report, Helsana is ensuring greater transparency in the healthcare sector, and thus helping to improve the care that our customers receive.
he latest Helsana Drug Report shows that the medication costs borne by basic insurance have reached a new high of CHF 7.6 billion in 2018. The challenge of ensuring high-quality medical care at an acceptable cost has intensified. The 6th edition of the Helsana Drug Report focusses on analyses of antibiotics and clinically relevant drug combinations.
There has been a worldwide increase in the number of infections with antibiotic-resistant bacteria. Lots of things are being done in Switzerland to reduce the use of antibiotics. The Drug Report shows that about 20 per cent of the population purchases at least one antibiotic annually. It is evident that in the majority of cases, broad-spectrum antibiotics are prescribed instead of drugs which are effective against specific ailments.
If certain drugs are combined with each other, such as specific blood thinners and gastric acid inhibitors, this can result in negative interactions. The analysis of ten selected drug combinations highlights great room for improvement where drug quality is concerned.
The Helsana Drug Report is unique in Switzerland. The report – compiled in cooperation with the University Hospital of Basel (USB) and the European Centre of Pharmaceutical Medicine (ECPM) at the University of Basel – provides authentic insights into the supply of medicinal products in Switzerland. We also cast a critical eye on the market for medicinal products, look for anomalies and differences, and identify room for improvement. We do so from the perspective of our customers and in our role as the "trustee" of Swiss premium payers.
The report contains assessments of market trends based on our own (anonymised) statement data and provides a representative picture of the number of recipients of medication and the resulting costs. We also provide an in-depth analysis of selected indications and medication groups. The focus falls on the transparent representation of real trends.
The report is in German. The preface and summary are available in English, German and French.
We're here to help.